大和发表研究报告指，药明康德昨日收市后发盈喜，料中期收入208亿元，同比增长20.6%，其中持续经营业务收入增长约24.2%；净利润86亿元，同比增长1.02倍；扣除非经常性损益的经调整净利润约63亿元，同比增长44%。该行估算，次季收入为111亿元，胜预期7%，意味着同比增长大幅增长20.4%。基于盈喜中预期中期收入达208亿元，该行认为公司正逐步达成全年收入415亿至430亿元的指引。基于其收入前景清晰，利润率改善，以及强劲的订单积压，该行予其“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.